Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Mecasermin: Difference between pages

{{Short description|Pharmaceutical drug}}

| Watchedfields = changed

| verifiedrevid = 462101108

| image =

<!-- Clinical data -->

| tradename = Increlex

| pregnancy_AU = B3

| pregnancy_category = <ref name="Increlex APMDS" />

| routes_of_administration = [[Subcutaneous injection]]

| ATC_prefix = H01

| ATC_suffix = AC03

| legal_AU = S4

| legal_AU_comment = <ref name="Increlex APMDS">https://www.tga.gov.au/resources/auspmd/increlex</ref>

| legal_CA = Rx-only

| legal_CA_comment = /&nbsp;Schedule D<ref>{{cite web | title=Summary Basis of Decision (SBD) for Increlex | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00524&lang=en | access-date=29 May 2022}}</ref>

| legal_US_comment = <ref name="Increlex FDA label">{{cite web | title=Increlex- mecasermin injection, solution | website=DailyMed | date=7 May 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8b27a1b-a611-4f91-ad22-76d4b390c3ae | access-date=30 May 2022}}</ref>

| legal_status =

<!-- Pharmacokinetic data -->

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life = 5.8 hours<ref name="Increlex FDA label" />

| excretion =

<!-- Identifiers -->

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 68562-41-4

| PubChem =

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB01277

| UNII_Ref = {{fdacite|correct|FDA}}

| KEGG = D04870

| ChEMBL = 1201716

| ChemSpiderID = none

| synonyms = FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1

<!-- Chemical data -->

| IUPAC_name =

| C=331 | H=512 | N=94 | O=101 | S=7

'''Mecasermin''', sold under the brand name '''Increlex''', also known as '''recombinant human insulin-like growth factor-1''' ('''rhIGF-1'''), is a [[recombinant DNA|recombinant]] form of human [[insulin-like growth factor 1]] (IGF-I) which is used in the long-term treatment of [[growth failure]] and [[short stature]] in children with severe primary IGF-I deficiency, for instance due to [[growth hormone deficiency]] or [[Laron syndrome]] ([[growth hormone]] insensitivity).<ref name="Increlex FDA label" /><ref>{{cite journal | vauthors = Fintini D, Brufani C, Cappa M | title = Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency | journal = Therapeutics and Clinical Risk Management | volume = 5 | issue = 3 | pages = 553–9 | date = June 2009 | pmid = 19707272 | pmc = 2724186 | doi = 10.2147/tcrm.s6178 | doi-access = free }}</ref><ref>{{cite web|url=https://www.drugs.com/increlex.html|title=Increlex|publisher=Drugs.com|access-date=10 January 2010}}</ref>

Mecasermin has a [[biological half-life]] of about 5.8&nbsp;hours in children with severe primary IGF-1 deficiency.<ref name="Increlex FDA label" />

A related medication is [[mecasermin rinfabate]] (brand name Iplex), which is a combination of mecasermin (rhIGF-1), [[insulin-like growth factor binding protein-3]] (IGFBP-3), and [[insulin-like growth factor binding protein acid labile subunit]] (IGFALS) as a [[ternary complex]].<ref name="Iplex-Label">{{cite web | title = Iplex (mecasermin rinfabate [rDNA origin] injection) Package Insert | work = U.S. Food and Drug Administration | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021884s001lbl.pdf }}</ref> The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4&nbsp;hours in individuals with severe primary IGF-1 deficiency.<ref name="Iplex-Label" />

Mecasermin therapy has been also shown to be beneficial in other conditions not related to growth failure, including [[Diabetes|diabetes mellitus]] and [[anorexia nervosa]].<ref name="Mecasermin">{{cite journal |vauthors=Keating GM |date=2008 |title=Mecasermin |journal=BioDrugs |volume=22 |issue=3 |pages=177–188 |doi=10.2165/00063030-200822030-00004 |pmid=18481900}}</ref>

== References ==

{{Reflist}}

{{Growth factor receptor modulators}}

{{Portal bar | Medicine}}

[[Category:Endocrinology]]

[[Category:Growth hormones]]

[[Category:Insulin-like growth factor receptor agonists]]

[[Category:Insulin receptor agonists]]

[[Category:Peptide therapeutics]]

{{Systemic-hormonal-drug-stub}}